Legal News

Patents Court confirms that administrative error means Genentech’s ranibizumab SPC will lapse earlier than the maximum permitted period of duration (Master Data v Comptroller and Genentech v Comptroller)

Patents Court confirms that administrative error means Genentech’s ranibizumab SPC will lapse earlier than the maximum permitted period of duration (Master Data v Comptroller and Genentech v Comptroller)
Published on: 13 March 2020
Published by: LexisPSL
  • Patents Court confirms that administrative error means Genentech’s ranibizumab SPC will lapse earlier than the maximum permitted period of duration (Master Data v Comptroller and Genentech v Comptroller)
  • What are the practical implications of this case?
  • What was the background?
  • The Hearing Officer’s decision
  • What did the court decide?
  • Master Data’s appeal
  • Genentech’s appeal
  • Case details

Article summary

Life Sciences analysis: The Patents Court has dismissed Genentech and Master Data Centre’s appeal against the Comptroller General of Patents’ decision that Genentech’s Supplementary Protection Certificate (SPC) for ranibizumab will lapse on 2 April 2020, ie earlier than the maximum permitted period of duration, due to Master Data (Genentech’s patent administration company) making a mistake and only requesting and paying for a two-year term, rather than the desired four-year term. or take a trial to read the full analysis.

Popular documents